Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
12.97B
Market cap12.97B
Price-Earnings ratio
-51.12
Price-Earnings ratio-51.12
Dividend yield
Dividend yield
Average volume
701.46K
Average volume701.46K
High today
$217.73
High today$217.73
Low today
$208.01
Low today$208.01
Open price
$217.73
Open price$217.73
Volume
542.24K
Volume542.24K
52 Week high
$223.19
52 Week high$223.19
52 Week low
$118.03
52 Week low$118.03

Stock Snapshot

Ascendis Pharma(ASND) stock is priced at $210.22, giving the company a market capitalization of 12.97B. It carries a P/E multiple of -51.12.

During the trading session on 2025-11-19, Ascendis Pharma(ASND) shares reached a daily high of $217.73 and a low of $208.01. At a current price of $210.22, the stock is +1.1% higher than the low and still -3.4% under the high.

Trading activity shows a volume of 542.24K, compared to an average daily volume of 701.46K.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

ASND News

TipRanks 2d
Ascendis Pharma initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $255 price target Yorvipath is off to a “strong” launch and “the party...

TipRanks 2d
Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics

Ascendis Pharma (ASND) announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly...

Simply Wall St 5d
How Investors Are Reacting To Ascendis Pharma Achieving First Positive Operating Income and Pooled Data Milestone

Ascendis Pharma reported third-quarter 2025 results showing revenue of €213.63 million and a net loss of €60.99 million, with improved financial performance, gl...

How Investors Are Reacting To Ascendis Pharma Achieving First Positive Operating Income and Pooled Data Milestone

Analyst ratings

100%

of 15 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

Simply Wall St 6d
Ascendis Pharma (NasdaqGS:ASND): Is There More Value Left After Strong Shareholder Returns?

Ascendis Pharma (NasdaqGS:ASND) has caught the attention of investors, with shares fluctuating over the past month. The company’s stock performance reflects shi...

Ascendis Pharma (NasdaqGS:ASND): Is There More Value Left After Strong Shareholder Returns?
TipRanks 7d
Ascendis Pharma: Promising Growth and Strong Market Penetration Justify Buy Rating

Analyst Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma and increased the price target to $220.00 from $212.00. Meet Your ETF AI Analyst Disco...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.